American Well Corporation

Análisis de la acción American Well Corporation (AMWL)

$11.930

+0.183 (+1.53%)Al cierre

Loading chart…
High
12.050
Open
11.850
VWAP
11.90
Vol
43.69K
Mkt Cap
111.26M
Low
11.715
Amount
519.79K
EV/EBITDA, TTM
-0.79

American Well Corporation operates a hybrid care, delivery enablement platform in the United States and globally, connecting and enabling providers, payers, patients, and innovators to deliver access to more affordable quality care. It offers a single, comprehensive platform to support all digital health needs from urgent to acute and post-acute care, as well as chronic care management and healthy living. The Amwell Converge platform offers data architecture and video capabilities, flexibility and scalability, as well as a user experience focused on the needs of patients, members and providers. For health systems, its enterprise platform enables provider-to-provider virtual care for use cases ranging from stroke to virtual nursing and e-sitting. Its Amwell Carepoint devices enable healthcare providers to leverage proprietary carts and transform existing tablets and TVs into digital access points in clinical settings, helping to address personnel shortages and access limitations.

AI analysis of American Well Corporation (AMWL)

buy

American Well Corp (AMWL) is a good buy right now, trading at $11.93 with a strong year-to-date change of +145.98%. The company has shown resilience with a narrowed net loss of $9.6 million in Q2 2026, and revenue guidance for Q3 is set between $46 million and $48 million, indicating potential for growth. However, the main risk is the forward P/E of 0, suggesting uncertainty in profitability expectations.

Métricas de valoración

The current forward P/E ratio for American Well Corporation (AMWL) is 0.00, compared to its 5-year average forward P/E of -9.68.

Forward P/E

Fair
5Y Average P/E
-9.68
Current P/E
0.00
Sobrevalorada
15.68
Infravalorada
-35.04

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
-0.37
Current EV/EBITDA
-0.79
Sobrevalorada
2.46
Infravalorada
-3.21

Forward P/S

Fair
5Y Average P/S
1.95
Current P/S
0.95
Sobrevalorada
3.90
Infravalorada
0.01

Alphio AI Price Scenarios for AMWL

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%AMWL

$8.60

Precio del escenario

B

Base

Base · 50%AMWL

$7.73

Precio del escenario

B

Bear

Bear · 25%AMWL

$7.23

Precio del escenario

Whales holding AMWL

S

Senvest Management, LLC

+ HoldingAMWL

+0.03%

3M Return

Cronología de eventos

2026-08-04 (ET)

17:00:00

Sees Q3 Adjusted EBITDA Loss of $3M-$5M

17:00:00

Amwell Reports Q2 Revenue of $52.05M, Exceeding Expectations

17:00:00

Adjusts FY26 EBITDA Loss Outlook to $7M-$9M

2026-02-12 (ET)

16:30:00

Sees Q1 Adjusted EBITDA in Range of ($7M)-($5M)

16:30:00

Amwell Reports Q4 Revenue of $55.3M, Exceeds Expectations

Noticias

AMWL FAQ — answered by Alphio AI

American Well Corporation operates a hybrid care, delivery enablement platform in the United States and globally, connecting and enabling providers, payers, patients, and innovators to deliver access to more affordable quality care. It offers a single, comprehensive platform to support all digital health needs from urgent to acute and post-acute care, as well as chronic care management and healthy living. The Amwell Converge platform offers data architecture and video capabilities, flexibility and scalability, as well as a user experience focused on the needs of patients, members and providers. For health systems, its enterprise platform enables provider-to-provider virtual care for use cases ranging from stroke to virtual nursing and e-sitting. Its Amwell Carepoint devices enable healthcare providers to leverage proprietary carts and transform existing tablets and TVs into digital access points in clinical settings, helping to address personnel shortages and access limitations. It operates in the Healthcare sector (SERVICES-BUSINESS SERVICES, NEC industry).

American Well Corp (AMWL) is a good buy right now, trading at $11.93 with a strong year-to-date change of +145.98%. The company has shown resilience with a narrowed net loss of $9.6 million in Q2 2026, and revenue guidance for Q3 is set between $46 million and $48 million, indicating potential for growth. However, the main risk is the forward P/E of 0, suggesting uncertainty in profitability expectations.

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empieza gratis